Gilead Sciences consensus stays robust, analysts stick to Moderate Buy rating

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-26, 11:51.

Gilead Sciences (US3755581036) sits in focus on NASDAQ with a clear analyst picture. The large-cap biotech continues to carry a "Moderate Buy" consensus rating from 29 Wall Street analysts, according to recent data from MarketBeat and other aggregators. MarketBeat consensus overview for Gilead Sciences

What the analyst consensus shows

Across 29 analyst opinions compiled over the past 12 months, 25 rate Gilead Sciences shares as Buy and 4 as Hold, with no active Sell recommendations reported on MarketBeat. MarketBeat breakdown of Gilead ratings The same dataset indicates an average 12-month price target around 124 US dollars per share, based on NASDAQ trading levels as of June 25, 2026. MarketBeat price target summary

The consensus label "Moderate Buy" places Gilead between pure Buy favorites and more mixed stories in the US biotech space, where peers like Amgen and Biogen attract more diverse views on valuation and pipeline risk. Reuters sector commentary on large-cap biotech

Rating distribution and price targets

MarketBeat data show that individual price targets for Gilead Sciences cluster in a band around the low to mid-120s in US dollars, with the highest published target notably above the current price and the lowest still close to spot NASDAQ levels. MarketBeat Gilead target range The consensus target near 124 US dollars implies moderate upside versus the most recent closing print at about 123.84 US dollars on June 25, 2026, at 16:00 Eastern, based on MarketBeat’s quote snapshot. MarketBeat Gilead quote page

With 25 Buy recommendations, the rating distribution indicates that most covering analysts see Gilead as an attractive position in the S&P 500 health care segment, where defensive cash flows and established drug franchises carry particular weight in portfolio construction. Bloomberg analysis on US healthcare positioning

The products behind Gilead’s revenue

Gilead Sciences generates a large share of its revenue from antiviral therapies, including HIV combination treatments such as Biktarvy and Descovy, along with hepatitis C and hepatitis B medicines and newer cell therapies in oncology, according to recent company reports. Gilead financial reporting overview

Where the shares trade today

The Gilead Sciences shares (US3755581036) last closed on NASDAQ on 2026-06-25 at 123.84 US dollars at 16:00 Eastern, with an after-hours indication around 125.30 US dollars at 19:24 Eastern based on MarketBeat data. MarketBeat Gilead extended-hours quote

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. All data were obtained from sources deemed reliable but cannot be guaranteed. Investors should conduct their own research and, where appropriate, consult a qualified financial adviser.